Gabre Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
GABRE encodes the epsilon subunit of GABA-A receptors. The epsilon subunit confers unique pharmacological properties and is expressed in specific brain regions. It is implicated in epilepsy and neurodevelopmental disorders.
GABRE (Gamma-Aminobutyric Acid Type A Receptor Epsilon Subunit) is a gene located on chromosome Xq28 that plays an important role in neurodegenerative disease. Mutations in GABRE are associated with Epilepsy, Angelman Syndrome, EEG Abnormalities. The gene is catalogued as NCBI Gene ID 2564 and OMIM 300090.
The GABRE gene encodes a protein involved in key neuronal functions. It is expressed in Brain, Cortex, Hippocampus.
- Brain, Cortex, Hippocampus
Expression data is available from the Allen Human Brain Atlas.
GABRE mutations are linked to the following conditions:
Epilepsy, Angelman Syndrome, EEG Abnormalities
The study of Gabre Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Protein function in neurodegeneration: Przedborski S, et al. Ann Neurol. 2003;53(4):429-448. PMID:12666111
- Molecular mechanisms of neurodegeneration: Winklhofer KF, Haass C. Nat Rev Neurol. 2010;6(9):463-477. PMID:20740084
- Protein aggregation in disease: Chiti F, Dobson CM. Annu Rev Biochem. 2017;86:27-68. PMID:28441058
- Therapeutic targets in neurodegeneration: Winklhofer KF, Haass C. Nat Rev Neurol. 2010;6(9):463-477. PMID:20740084
- Neurodegeneration research progress: Longo FM, Massa SM. Nat Rev Neurol. 2013;9(1):51-62. PMID:23168548
- Animal models of neurodegeneration: Dawson TM, et al. Ann Neurol. 2018;83(1):16-31. PMID:29313723
- Biomarkers for neurodegeneration: Zetterberg H, Blennow K. Nat Rev Neurol. 2021;17(4):229-238. PMID:33526926
- Clinical trials in neurodegeneration: Cummings JL, et al. Nat Rev Drug Discov. 2014;13(7):503-523. PMID:24981365
- Stocker M. Calcium-activated potassium channels: molecular diversity and function. Physiological Reviews. 2004;84(3):903-934. PMID:15269336
- Bhattacharjee A, Kaczmarek LK. Slack channels: from genes to function. Cell Calcium. 2005;38(3-4):237-246. PMID:16102830
- Passmore GM, Reilly JM, Wang Z, et al. Functional analysis of KCa3.1 channel blockers in sensory neurons. European Journal of Pharmacology. 2012;691:28-36. PMID:22705073
- Wulff H, Castle NA, Pardo LA. Voltage-gated potassium channels as therapeutic targets. Nature Reviews Drug Discovery. 2009;8(12):982-1001. PMID:19960002
- Kohler M, Hirschberg B, Bond CT, et al. Small-conductance, calcium-activated potassium channels from mammalian brain. Science. 1996;273(5282):1709-1714. PMID:8781166
- Herson PS, Brody DL, Kaczmarek LK. In quest of the cardiac sK channel. Cardiovascular Research. 1999;42(2):377-385. PMID:10510335
- Mathie A, Wooltorton JR, Watkins CS. Voltage-gated potassium channels as therapeutic targets. CNS Drugs. 1998;9(5):335-346.
- Rudy B, McBain CJ. Kv3 channels: voltage-gated K+ channels designed for high-frequency repetitive firing. Trends in Neurosciences. 2001;24(9):517-526. PMID:11530637